Initial decline in estimated glomerular filtration rate after empagliflozin in patients with acute heart failure: insights from EMPULSE
Abstract
This research aims to explore the effects of certain diabetes medications, specifically sodium-glucose cotransporter 2 inhibitors (SGLT2i), on kidney function in patients experiencing heart failure. Heart failure is a serious condition affecting millions of people worldwide, where the heart struggles to pump enough blood. Many patients with heart failure also have diabetes, making understanding the impact of diabetes medications crucial. SGLT2i are medications that help lower blood sugar levels in people with diabetes by preventing the reabsorption of glucose in the kidneys. Medications like empagliflozin are known to help reduce the risk of death from heart-related issues and lower the chances of hospitalization due to heart failure. However, they can cause a temporary drop in kidney function, which is measured using a test called estimated glomerular filtration rate (eGFR). An initial decline in estimated glomerular filtration rate (eGFR), known as an "eGFR dip," commonly occurs after starting sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with diabetes and heart failure, but can be concerning. Previous studies primarily focused on patients with chronic (long-term) heart failure. In contrast, our research targets those with acute (sudden) heart failure, where kidney function can change more rapidly and its effects on patient outcomes are less understood. Interestingly, in some cases, worsening kidney function during hospital stays might actually correlate…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.